Loading...

HTG Molecular Diagnostics

DB:65H
Snowflake Description

Adequate balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
65H
DB
$74M
Market Cap
  1. Home
  2. DE
  3. Healthcare
Company description

HTG Molecular Diagnostics, Inc. a commercial stage life sciences company, focuses on the precision medicine. The last earnings update was 42 days ago. More info.


Add to Portfolio Compare Print
65H Share Price and Events
7 Day Returns
-16.3%
DB:65H
0.6%
DE Healthcare Services
2.5%
DE Market
1 Year Returns
-18.7%
DB:65H
18.3%
DE Healthcare Services
-6.7%
DE Market
65H Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
HTG Molecular Diagnostics (65H) -16.3% 6.9% 14.5% -18.7% - -
DE Healthcare Services 0.6% 5.5% 26.2% 18.3% 49.2% 159.9%
DE Market 2.5% 3.3% 9.2% -6.7% 9% 13.5%
1 Year Return vs Industry and Market
  • 65H underperformed the Healthcare Services industry which returned 18.3% over the past year.
  • 65H underperformed the Market in Germany which returned -6.7% over the past year.
Price Volatility
65H
Industry
5yr Volatility vs Market

Value

 Is HTG Molecular Diagnostics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for HTG Molecular Diagnostics. This is due to cash flow or dividend data being unavailable. The share price is €2.245.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for HTG Molecular Diagnostics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are HTG Molecular Diagnostics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:65H PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-0.60
NasdaqCM:HTGM Share Price ** NasdaqCM (2019-04-18) in USD $2.57
Germany Healthcare Services Industry PE Ratio Median Figure of 5 Publicly-Listed Healthcare Services Companies 29.76x
Germany Market PE Ratio Median Figure of 421 Publicly-Listed Companies 19.69x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of HTG Molecular Diagnostics.

DB:65H PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:HTGM Share Price ÷ EPS (both in USD)

= 2.57 ÷ -0.60

-4.3x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • HTG Molecular Diagnostics is loss making, we can't compare its value to the DE Healthcare Services industry average.
  • HTG Molecular Diagnostics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does HTG Molecular Diagnostics's expected growth come at a high price?
Raw Data
DB:65H PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -4.3x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
-0.3%per year
Europe Healthcare Services Industry PEG Ratio Median Figure of 12 Publicly-Listed Healthcare Services Companies 2.01x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for HTG Molecular Diagnostics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on HTG Molecular Diagnostics's assets?
Raw Data
DB:65H PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $0.74
NasdaqCM:HTGM Share Price * NasdaqCM (2019-04-18) in USD $2.57
Germany Healthcare Services Industry PB Ratio Median Figure of 7 Publicly-Listed Healthcare Services Companies 2.08x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.87x
DB:65H PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:HTGM Share Price ÷ Book Value per Share (both in USD)

= 2.57 ÷ 0.74

3.48x

* Primary Listing of HTG Molecular Diagnostics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • HTG Molecular Diagnostics is overvalued based on assets compared to the DE Healthcare Services industry average.
X
Value checks
We assess HTG Molecular Diagnostics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Healthcare Services industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Healthcare Services industry average (and greater than 0)? (1 check)
  5. HTG Molecular Diagnostics has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is HTG Molecular Diagnostics expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-0.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is HTG Molecular Diagnostics expected to grow at an attractive rate?
  • Unable to compare HTG Molecular Diagnostics's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare HTG Molecular Diagnostics's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • HTG Molecular Diagnostics's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:65H Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:65H Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts -0.3%
DB:65H Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts 21.7%
Germany Healthcare Services Industry Earnings Growth Rate Market Cap Weighted Average 6.5%
Europe Healthcare Services Industry Revenue Growth Rate Market Cap Weighted Average 7.4%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.7%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:65H Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:65H Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 39 -17 2
2020-12-31 32 -17 -17 4
2019-12-31 25 -18 -18 5
DB:65H Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 22 -13 -16
2018-09-30 22 -13 -16
2018-06-30 21 -14 -17
2018-03-31 18 -15 -19
2017-12-31 15 -17 -19
2017-09-30 8 -19 -23
2017-06-30 6 -19 -24
2017-03-31 6 -21 -25
2016-12-31 5 -22 -26
2016-09-30 5 -22 -26
2016-06-30 5 -22 -25
2016-03-31 4 -21 -25

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • HTG Molecular Diagnostics is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • HTG Molecular Diagnostics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:65H Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from HTG Molecular Diagnostics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:65H Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31 -0.35 -0.35 -0.35 1.00
2020-12-31 -0.43 -0.42 -0.44 2.00
2019-12-31 -0.60 -0.56 -0.64 3.00
DB:65H Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -0.60
2018-09-30 -0.69
2018-06-30 -0.86
2018-03-31 -1.25
2017-12-31 -1.79
2017-09-30 -2.46
2017-06-30 -2.95
2017-03-31 -3.36
2016-12-31 -3.66
2016-09-30 -3.75
2016-06-30 -3.58
2016-03-31 -4.02

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if HTG Molecular Diagnostics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess HTG Molecular Diagnostics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Europe market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
HTG Molecular Diagnostics has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has HTG Molecular Diagnostics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare HTG Molecular Diagnostics's growth in the last year to its industry (Healthcare Services).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • HTG Molecular Diagnostics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare HTG Molecular Diagnostics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare HTG Molecular Diagnostics's 1-year growth to the DE Healthcare Services industry average as it is not currently profitable.
Earnings and Revenue History
HTG Molecular Diagnostics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from HTG Molecular Diagnostics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:65H Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 21.50 -16.45 19.97 12.60
2018-09-30 21.68 -16.25 19.74 12.54
2018-06-30 20.70 -16.79 19.28 12.46
2018-03-31 17.55 -18.52 18.93 11.32
2017-12-31 14.76 -18.96 17.51 10.00
2017-09-30 8.31 -22.71 16.99 7.75
2017-06-30 5.50 -23.82 16.67 6.18
2017-03-31 5.64 -24.83 16.97 7.17
2016-12-31 5.13 -26.04 17.43 7.90
2016-09-30 4.89 -26.07 17.46 8.17
2016-06-30 4.99 -24.74 17.23 7.57
2016-03-31 3.88 -24.75 16.25 5.91
2015-12-31 4.04 -22.73 14.99 4.60
2015-09-30 4.12 -22.10 13.66 3.65
2015-06-30 3.98 -21.06 12.56 2.99
2015-03-31 3.53 -18.97 11.26 2.91
2014-12-31 3.33 -17.62 9.90 3.08
2014-09-30 2.65 -15.86 8.60 3.43
2014-06-30 2.29 -15.10 7.90 3.31
2014-03-31 2.51 -14.08 7.63 3.75
2013-12-31 2.24 -14.19 7.71 4.20
2012-12-31 2.48 -14.28 7.29 3.92

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if HTG Molecular Diagnostics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if HTG Molecular Diagnostics has efficiently used its assets last year compared to the DE Healthcare Services industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if HTG Molecular Diagnostics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess HTG Molecular Diagnostics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Healthcare Services industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
HTG Molecular Diagnostics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is HTG Molecular Diagnostics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up HTG Molecular Diagnostics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • HTG Molecular Diagnostics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • HTG Molecular Diagnostics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of HTG Molecular Diagnostics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 3.9x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from HTG Molecular Diagnostics Company Filings, last reported 3 months ago.

DB:65H Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 21.09 9.68 31.11
2018-09-30 22.79 9.64 33.78
2018-06-30 27.21 9.59 40.73
2018-03-31 30.97 9.55 45.66
2017-12-31 -3.06 8.75 9.97
2017-09-30 -4.52 7.36 9.05
2017-06-30 -1.55 8.88 13.40
2017-03-31 -10.96 10.35 5.38
2016-12-31 -5.59 11.78 11.81
2016-09-30 -2.21 13.16 16.62
2016-06-30 4.02 14.49 22.92
2016-03-31 10.56 15.78 30.15
2015-12-31 16.89 10.80 31.50
2015-09-30 22.44 10.76 31.31
2015-06-30 27.49 10.67 29.63
2015-03-31 -16.66 12.87 1.56
2014-12-31 -13.02 10.52 3.61
2014-09-30 -9.23 10.39 7.69
2014-06-30 -6.35 0.75 2.71
2014-03-31 -7.34 0.00 1.82
2013-12-31 -7.34 0.00 1.82
2012-12-31 -3.02 0.00 7.32
  • HTG Molecular Diagnostics's level of debt (45.9%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0% vs 45.9% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • HTG Molecular Diagnostics has sufficient cash runway for 2.2 years based on current free cash flow.
  • HTG Molecular Diagnostics has sufficient cash runway for 2.5 years if free cash flow continues to reduce at historical rates of -17% each year.
X
Financial health checks
We assess HTG Molecular Diagnostics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. HTG Molecular Diagnostics has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is HTG Molecular Diagnostics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from HTG Molecular Diagnostics dividends.
If you bought €2,000 of HTG Molecular Diagnostics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate HTG Molecular Diagnostics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate HTG Molecular Diagnostics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:65H Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
Europe Healthcare Services Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 1.5%
Germany Market Average Dividend Yield Market Cap Weighted Average of 324 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:65H Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as HTG Molecular Diagnostics has not reported any payouts.
  • Unable to verify if HTG Molecular Diagnostics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of HTG Molecular Diagnostics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as HTG Molecular Diagnostics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess HTG Molecular Diagnostics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can HTG Molecular Diagnostics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. HTG Molecular Diagnostics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of HTG Molecular Diagnostics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
John Lubniewski
COMPENSATION $1,297,753
AGE 54
TENURE AS CEO 0 years
CEO Bio

Mr. John L. Lubniewski serves as Director at HTG Molecular Diagnostics, Inc. since April 2019. Mr. Lubniewski serves as President since April 2018 and served as Chief Operating Officer at HTG Molecular Diagnostics, Inc. since April 16, 2018 until 2019 and serves as its Chief Executive Officer since April 2019. Mr. served as Vice President and Chief Business Officer of HTG Molecular Diagnostics, Inc. since April 2011 until April 16, 2018. Mr. Lubniewski was responsible for leading the sales, marketing and product development teams for HTG's three strategic business areas: molecular testing capabilities for translational medicine, pharmaceutical clinical development and pathology laboratory diagnostics. He joined HTG from Ventana, a medical diagnostics company and member of the Roche Group and global headquarters of Roche Tissue Diagnostics, or RTD. During his time at Ventana, Mr. Lubniewski served in several senior leadership roles and was responsible for marketing and global accountability for all clinical assay products. Prior to the acquisition by Roche, Mr. Lubniewski was responsible for a variety of assay and platform development and commercialization efforts across the company. Prior to Ventana, Mr. Lubniewski spent over a decade working at Corning, Inc., a manufacturing company, in a variety of roles including divisional, sector, and corporate sales, and marketing roles. Mr. Lubniewski earned a B.S. in Chemical Engineering from Clarkson University.

CEO Compensation
  • John's compensation has increased whilst company is loss making.
  • John's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the HTG Molecular Diagnostics management team in years:

5
Average Tenure
58
Average Age
  • The average tenure for the HTG Molecular Diagnostics management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

John Lubniewski

TITLE
President
COMPENSATION
$1M
AGE
54

Shaun McMeans

TITLE
Senior VP of Finance & Administration
COMPENSATION
$1M
AGE
56
TENURE
7.2 yrs

Maureen Cronin

TITLE
Senior VP & Chief Scientific Officer
AGE
65
TENURE
0.4 yrs

Deb Gordon

TITLE
Senior VP & Chief Legal Counsel
COMPENSATION
$297K
AGE
58
TENURE
7.8 yrs

Sam Rua

TITLE
Senior Vice President of Regulatory Affairs & Quality Systems
AGE
58
TENURE
1.2 yrs

Pat Roche

TITLE
Senior Vice President of Research & Development
COMPENSATION
$507K
AGE
65
TENURE
5 yrs
Board of Directors Tenure

Average tenure and age of the HTG Molecular Diagnostics board of directors in years:

3.2
Average Tenure
59.5
Average Age
  • The tenure for the HTG Molecular Diagnostics board of directors is about average.
Board of Directors

Tim, TJ Johnson

TITLE
Executive Chairman
COMPENSATION
$2M
AGE
57
TENURE
0.1 yrs

John Lubniewski

TITLE
President
COMPENSATION
$1M
AGE
54

Don Hardison

TITLE
Director
COMPENSATION
$86K
AGE
67
TENURE
2.9 yrs

Ann Hanham

TITLE
Lead Independent Director
COMPENSATION
$114K
AGE
65

Michelle Griffin

TITLE
Director
COMPENSATION
$85K
AGE
52
TENURE
0.7 yrs

Harry George

TITLE
Director
COMPENSATION
$84K
AGE
70
TENURE
17.3 yrs

Lee McCracken

TITLE
Director
COMPENSATION
$85K
AGE
60
TENURE
3.5 yrs

Jim LaFrance

TITLE
Director
COMPENSATION
$93K
AGE
59
TENURE
3.3 yrs

James Gulley

TITLE
Member of Scientific Advisory Board
TENURE
3.2 yrs

Fred Hirsch

TITLE
Member of Scientific Advisory Board
TENURE
3.2 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess HTG Molecular Diagnostics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. HTG Molecular Diagnostics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

HTG Molecular Diagnostics, Inc. a commercial stage life sciences company, focuses on the precision medicine. The company offers instrumentation (or platforms); consumables comprising assay kits; and software analytics that automate sample processing and profiles various molecular targets. Its platforms generate a molecular profiling library for detection using next-generation sequencing. The company’s assay product offerings include HTG EdgeSeq oncology biomarker panel; HTG EdgeSeq immuno-oncology assay; HTG EdgeSeq DLBCL Cell of Origin Assay; HTG EdgeSeq PATH Assay; HTG EdgeSeq miRNA Whole-Transcriptome Assay; HTG EdgeSeq DLBCL Cell of Origin Assay EU; HTG EdgeSeq ALKPlus Assay EU; HTG EdgeSeq EGFR, KRAS and BRAF Mutation Assay; and HTG EdgeSeq Precision Immuno-Oncology Panel. It serves biopharmaceutical companies, academic research centers, and molecular testing laboratories. HTG Molecular Diagnostics, Inc. distributes its instruments and consumables directly in the United States and Europe; and through distributors in parts of Europe and internationally. The company has a collaboration agreement with Bristol-Myers Squibb for the development of custom RUO assays; governing agreement with QIAGEN Manchester Limited; and development and professional services agreement with Invetech PTY Ltd. The company was formerly known as HTG, Inc. and changed its name to HTG Molecular Diagnostics, Inc. in March 2011. HTG Molecular Diagnostics, Inc. was incorporated in 1997 and is based in Tucson, Arizona.

Details
Name: HTG Molecular Diagnostics, Inc.
65H
Exchange: DB
Founded: 1997
$65,401,124
28,606,012
Website: http://www.htgmolecular.com
Address: HTG Molecular Diagnostics, Inc.
3430 East Global Loop,
Tucson,
Arizona, 85706,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM HTGM Common Stock Nasdaq Capital Market US USD 07. May 2015
DB 65H Common Stock Deutsche Boerse AG DE EUR 07. May 2015
Number of employees
Current staff
Staff numbers
108
HTG Molecular Diagnostics employees.
Industry
Health Care Technology
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/18 22:32
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/08
Last earnings filing: 2019/03/07
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.